Vanguard Group Inc. Buys 74,037 Shares of Cryoport, Inc. (NASDAQ:CYRX)

→ Biden replacement revealed? (From Paradigm Press) (Ad)

Vanguard Group Inc. increased its position in shares of Cryoport, Inc. (NASDAQ:CYRX - Free Report) by 2.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,559,092 shares of the company's stock after buying an additional 74,037 shares during the quarter. Vanguard Group Inc. owned 7.27% of Cryoport worth $48,795,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. American Century Companies Inc. grew its position in Cryoport by 72.2% during the third quarter. American Century Companies Inc. now owns 27,018 shares of the company's stock worth $370,000 after buying an additional 11,324 shares in the last quarter. Deutsche Bank AG lifted its stake in Cryoport by 22.5% during the third quarter. Deutsche Bank AG now owns 24,430 shares of the company's stock worth $335,000 after purchasing an additional 4,492 shares during the period. Connors Investor Services Inc. lifted its stake in Cryoport by 32.2% during the third quarter. Connors Investor Services Inc. now owns 172,867 shares of the company's stock worth $2,364,000 after purchasing an additional 42,117 shares during the period. Comerica Bank bought a new position in Cryoport during the third quarter worth about $53,000. Finally, Advisors Capital Management LLC lifted its stake in Cryoport by 2.5% during the third quarter. Advisors Capital Management LLC now owns 78,993 shares of the company's stock worth $1,083,000 after purchasing an additional 1,947 shares during the period. 92.90% of the stock is owned by institutional investors and hedge funds.


Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Stephens restated an "equal weight" rating and set a $17.00 price target on shares of Cryoport in a research note on Wednesday, March 13th. Needham & Company LLC cut their price target on shares of Cryoport from $19.00 to $18.00 and set a "buy" rating for the company in a research note on Wednesday, March 13th. Jefferies Financial Group began coverage on shares of Cryoport in a research note on Thursday, April 4th. They set a "buy" rating and a $21.00 price target for the company. Finally, UBS Group lifted their target price on shares of Cryoport from $14.50 to $17.00 and gave the company a "neutral" rating in a research note on Friday, March 15th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $18.63.

Get Our Latest Stock Report on Cryoport

Cryoport Trading Up 1.1 %

CYRX stock traded up $0.21 during trading on Tuesday, hitting $18.83. The company had a trading volume of 264,050 shares, compared to its average volume of 458,151. The company has a quick ratio of 11.16, a current ratio of 11.73 and a debt-to-equity ratio of 0.82. The firm has a 50-day moving average price of $16.54 and a 200-day moving average price of $14.64. Cryoport, Inc. has a 12 month low of $9.00 and a 12 month high of $24.17. The stock has a market cap of $925.68 million, a price-to-earnings ratio of -8.56 and a beta of 1.60.

Cryoport (NASDAQ:CYRX - Get Free Report) last posted its quarterly earnings data on Tuesday, March 12th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.19). Cryoport had a negative return on equity of 11.86% and a negative net margin of 42.69%. The company had revenue of $57.26 million during the quarter, compared to the consensus estimate of $58.27 million. As a group, analysts predict that Cryoport, Inc. will post -1.31 earnings per share for the current year.

Insider Buying and Selling

In other Cryoport news, Director Ramkumar Mandalam sold 3,217 shares of Cryoport stock in a transaction on Friday, March 15th. The shares were sold at an average price of $14.68, for a total transaction of $47,225.56. Following the completion of the sale, the director now owns 43,187 shares of the company's stock, valued at approximately $633,985.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Cryoport news, Director Ramkumar Mandalam sold 3,217 shares of Cryoport stock in a transaction on Friday, March 15th. The shares were sold at an average price of $14.68, for a total transaction of $47,225.56. Following the completion of the sale, the director now owns 43,187 shares of the company's stock, valued at approximately $633,985.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jerrell Shelton sold 3,723 shares of the business's stock in a transaction on Monday, March 11th. The shares were sold at an average price of $16.35, for a total transaction of $60,871.05. Following the completion of the transaction, the chief executive officer now directly owns 636,951 shares of the company's stock, valued at approximately $10,414,148.85. The disclosure for this sale can be found here. Insiders sold 73,940 shares of company stock worth $1,147,538 in the last quarter. Insiders own 10.50% of the company's stock.

Cryoport Profile

(Free Report)

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.

See Also

Institutional Ownership by Quarter for Cryoport (NASDAQ:CYRX)

Should you invest $1,000 in Cryoport right now?

Before you consider Cryoport, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cryoport wasn't on the list.

While Cryoport currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Featured Articles and Offers

Search Headlines: